Fujifilm Diosynth Biotechnologies has officially opened a new biotechnology manufacturing facility in Billingham as part of a £30m investment drive.
The site, which was opened by The Duke of Gloucester was commissioned and constructed in under 15 months and is focused on mammalian cell culture.
Fujifilm said the facility has been designed for rapid further expansion to meet customer demand. The company is already working on its first customer project for the project.
This new capacity is the latest in a series of investments at both Fujifilm Diosynth Biotechnologies’ UK and Research Triangle Park, in the US, totalling £30m over the past two years.
Steve Bagshaw, managing director of Fujifilm Diosynth Biotechnologies UK, said he was “delighted” that the company had been able to build the new GMP mammalian cell culture manufacturing facility in such a short time frame.
“This new capacity, using the latest single-use technologies, provides our customers with a full life-cycle offering for mammalian cell culture biopharmaceuticals from our UK site, and complements our offering in microbial-based biologics.”